Active Biotech: Active Biotech AB Year-end report January - December 2012

Events for the full year 2012
Laquinimod

• Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology)
• Application submitted for regulatory approval in the EU, milestone payment of USD 5 M from Teva
• Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study) in the US
• Positive Crohn's Phase II data presented at the UEGW conference
• Teva expands the clinical development program to encompass new indications

                                          
TASQ     

• EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase III study
• overall survival data from Phase II study presented
• biomarker data presented at the ESMO conference
• Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate cancer and
  a second study into additional cancer forms
• Phase III study fully enrolled (1,245 patients); milestone payment of EUR 10 M from Ipsen           

           
ANYARA    

• Phase II/III study in renal cell cancer concluded
•  Results presented during Q1, 2013:
   - study did not achieve primary clinical endpoint
   - doubling of progression free survival and OS in 25 % of patients
   - planning of the continued clinical development ongoing

57-57            

• clinical trial of systemic sclerosis/scleroderma concluded
  
  

ISI                

• focus on patent submissions H1 2013
• project proceeds as planned

	Oct - Dec		Jan - Dec
(MSEK)	2012	2011	2012	2011
Net sales	91.5	3.3	227.9	234.6
Operating profit/loss	5.5	-94.7	-163.2	-100.9
Net profit/loss	0.1	-93.2	-175.0	-94.5
Profit/loss per share (SEK)	0.00	-1.35	-2.54	-1.38

For further information, please contact:

Tomas Leanderson, President and CEO Tel: [phone]                                         
Hans Kolam, CFO Tel: [phone]
                                                                               
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: [phone], Fax [phone]
This report is also available at www.activebiotech.com (http://www.activebiotech.com/)

Active Biotech AB Year-end report Jan-Dec 2012 (http://hugin.info/1002/R/1678129/547591.pdf)

---

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE

HUG#1678129